Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Adalimumab Biosimilar Market: By Product: Exemptia, Adalirel, Cipleumab, Others; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others; Regional Analysis; Historical Market and Forecast (2018-2028); Market Dynamics: SWOT Analysis; Value Chain Analysis; Competitive Landscape; Industry Events and Developments

Global Adalimumab Biosimilar Market Outlook

The global adalimumab biosimilar market is expected to grow at a CAGR of about 17.60% in the forecast period of 2023-2028, driven by the rising incidence of rheumatoid arthritis, especially amongst the rapidly growing geriatric population.

 

Global Adalimumab Biosimilar Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

North America, Asia Pacific, and Europe to be the Significant Regional Markets for Adalimumab Biosimilar

North America is expected to be one of the largest markets, owing to numerous large-scale testing laboratories worldwide. The rising incidence of rheumatoid arthritis and the growing geriatric population are among the major factors which are fuelling the market expansion in North America.

Due to extensive commercial advancements and growing biotechnology corporations in the province, Asia Pacific is anticipated to register sturdy growth over the projection period. The increasing focus to develop generic and biosimilar products in the emerging nations of Asia Pacific is estimated to fuel the global adalimumab biosimilar industry in the region.

Europe is expected to grow faster due to the rise in approvals of the new biosimilars, the ageing population, and increasing investments in the research and development of the new adalimumab biosimilars. For instance, in October 2018, Amgen Inc. launched AMGEVITA, a biosimilar of adalimumab.

 

Adalimumab Biosimilar: Market Segmentation

Adalimumab is a monoclonal antibody used to treat autoimmune illnesses, such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and others. It accomplishes this by blocking Tumour Necrosis Factor (TNF), a soluble inflammatory cytokine. This drug helps prevent further joint injury and preserve joint function by lowering joint swelling.

 

Global Adalimumab Biosimilar Market by Segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

By product, the market includes:

  • Exemptia
  • Adalirel
  • Cipleumab
  • Others

The several distribution channels of the market are:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

The regional markets for the adalimumab biosimilar industry can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

 

Global Adalimumab Biosimilar Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The Proliferation of Skin Disorders Augmenting the Market Growth

The most frequent illnesses that harm human health are skin disorders. Many skin disorders lead to lifelong disfigurement, stigma, and disability, and treating them effectively has become a significant concern for health organizations. In this context, a biosimilar of adalimumab has emerged as a feasible therapy option for persistent skin conditions like eczema. This aspect can significantly increase the size of the global adalimumab biosimilar industry throughout the forecast period. The multiple advantages, especially in treating psoriasis, adalimumab biosimilar is a preferred option for tackling skin disorders. The rising geriatric population and increasing public and private investment in pharmaceuticals will propel the market growth. Regulatory approvals for novel products motivate other companies to invest more in research and development and produce new inventions. Some global adalimumab biosimilar industry competitors are already working on new product development and portfolio expansion. For example, through a licencing deal with Cadila Healthcare, Glenmark Pharmaceuticals introduced ADALY, its adalimumab biosimilar medicine, in Mumbai in January 2018.

 

Key Industry Players in the Global Adalimumab Biosimilar Market

The report gives a detailed analysis of the following key players in the global adalimumab biosimilar industry, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Alfred E. Tiefenbacher (GmbH & Co. KG)
  • Amgen Inc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Limited
  • Cadila Pharmaceuticals Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Reliance Life Sciences Private Limited
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2022
Historical Period 2018-2022
Forecast Period 2023-2028
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product
  • Distribution Channel
  • Region
Breakup by Product
  • Exemptia
  • Adalirel
  • Cipleumab
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Alfred E. Tiefenbacher (GmbH & Co. KG)
  • Amgen Inc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Limited
  • Cadila Pharmaceuticals Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Reliance Life Sciences Private Limited
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Adalimumab Biosimilar Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Adalimumab Biosimilar Historical Market (2018-2022) 
    8.3    Global Adalimumab Biosimilar Market Forecast (2023-2028)
    8.4    Global Adalimumab Biosimilar Market by Product
        8.4.1    Exemptia 
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2018-2022)
            8.4.1.3    Forecast Trend (2023-2028)
        8.4.2    Adalirel
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2018-2022)
            8.4.2.3    Forecast Trend (2023-2028)
        8.4.3    Cipleumab
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2018-2022)
            8.4.3.3    Forecast Trend (2023-2028)
        8.4.4    Others
    8.5    Global Adalimumab Biosimilar Market by Distribution Channel
        8.5.1    Hospital Pharmacies
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2018-2022)
            8.5.1.3    Forecast Trend (2023-2028)
        8.5.2    Retail Pharmacies
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2018-2022)
            8.5.2.3    Forecast Trend (2023-2028)
        8.5.3    Others
    8.6    Global Adalimumab Biosimilar Market by Region       
        8.6.1    North America
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2018-2022) 
            8.6.1.3    Forecast Trend (2023-2028)
        8.6.2    Europe
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2018-2022) 
            8.6.2.3    Forecast Trend (2023-2028)
        8.6.3    Asia Pacific
            8.6.3.1    Market Share
            8.6.3.2    Historical Trend (2018-2022) 
            8.6.3.3    Forecast Trend (2023-2028)
        8.6.4    Latin America
            8.6.4.1    Market Share
            8.6.4.2    Historical Trend (2018-2022) 
            8.6.4.3    Forecast Trend (2023-2028)
        8.6.5    Middle East and Africa
            8.6.5.1    Market Share
            8.6.5.2    Historical Trend (2018-2022) 
            8.6.5.3    Forecast Trend (2023-2028)
9    North America Adalimumab Biosimilar Market Analysis
    9.1    United States of America 
        9.1.1    Market Share
        9.1.2    Historical Trend (2018-2022) 
        9.1.3    Forecast Trend (2023-2028)
    9.2    Canada
        9.2.1    Market Share
        9.2.2    Historical Trend (2018-2022) 
        9.2.3    Forecast Trend (2023-2028)
10    Europe Adalimumab Biosimilar Market Analysis
    10.1    United Kingdom
        10.1.1    Market Share
        10.1.2    Historical Trend (2018-2022) 
        10.1.3    Forecast Trend (2023-2028)
    10.2    Germany
        10.2.1    Market Share
        10.2.2    Historical Trend (2018-2022) 
        10.2.3    Forecast Trend (2023-2028)
    10.3    France
        10.3.1    Market Share
        10.3.2    Historical Trend (2018-2022) 
        10.3.3    Forecast Trend (2023-2028)
    10.4    Italy
        10.4.1    Market Share
        10.4.2    Historical Trend (2018-2022) 
        10.4.3    Forecast Trend (2023-2028)
    10.5    Others
11    Asia Pacific Adalimumab Biosimilar Market  Analysis
    11.1    China
        11.1.1    Market Share
        11.1.2    Historical Trend (2018-2022) 
        11.1.3    Forecast Trend (2023-2028)
    11.2    Japan
        11.2.1    Market Share
        11.2.2    Historical Trend (2018-2022) 
        11.2.3    Forecast Trend (2023-2028)
    11.3    India
        11.3.1    Market Share
        11.3.2    Historical Trend (2018-2022) 
        11.3.3    Forecast Trend (2023-2028)
    11.4    ASEAN
        11.4.1    Market Share
        11.4.2    Historical Trend (2018-2022) 
        11.4.3    Forecast Trend (2023-2028)
    11.5    Australia
        11.5.1    Market Share
        11.5.2    Historical Trend (2018-2022) 
        11.5.3    Forecast Trend (2023-2028)
    11.6    Others
12    Latin America Adalimumab Biosimilar Market Analysis
    12.1    Brazil
        12.1.1    Market Share
        12.1.2    Historical Trend (2018-2022) 
        12.1.3    Forecast Trend (2023-2028)
    12.2    Argentina
        12.2.1    Market Share
        12.2.2    Historical Trend (2018-2022) 
        12.2.3    Forecast Trend (2023-2028)
    12.3    Mexico
        12.3.1    Market Share
        12.3.2    Historical Trend (2018-2022) 
        12.3.3    Forecast Trend (2023-2028)
    12.4    Others
13    Middle East and Africa Adalimumab Biosimilar Market Analysis
    13.1    Saudi Arabia
        13.1.1    Market Share
        13.1.2    Historical Trend (2018-2022) 
        13.1.3    Forecast Trend (2023-2028)
    13.2    United Arab Emirates
        13.2.1    Market Share
        13.2.2    Historical Trend (2018-2022) 
        13.2.3    Forecast Trend (2023-2028)
    13.3    Nigeria
        13.3.1    Market Share
        13.3.2    Historical Trend (2018-2022) 
        13.3.3    Forecast Trend (2023-2028)
    13.4    South Africa
        13.4.1    Market Share
        13.4.2    Historical Trend (2018-2022) 
        13.4.3    Forecast Trend (2023-2028)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
    14.3    Key Indicators for Demand
    14.4    Key Indicators for Price
15    Value Chain Analysis
16    Competitive Landscape

    16.1    Market Structure
    16.2    Company Profiles
        16.2.1    Alfred E. Tiefenbacher (GmbH & Co. KG)
            16.2.1.1    Company Overview
            16.2.1.2    Product Portfolio
            16.2.1.3    Demographic Reach and Achievements
            16.2.1.4    Certifications
        16.2.2    Amgen Inc.
            16.2.2.1    Company Overview
            16.2.2.2    Product Portfolio
            16.2.2.3    Demographic Reach and Achievements
            16.2.2.4    Certifications
        16.2.3    Boehringer Ingelheim Pharmaceuticals, Inc.
            16.2.3.1    Company Overview
            16.2.3.2    Product Portfolio
            16.2.3.3    Demographic Reach and Achievements
            16.2.3.4    Certifications
        16.2.4    Glenmark Pharmaceuticals Limited
            16.2.4.1    Company Overview
            16.2.4.2    Product Portfolio
            16.2.4.3    Demographic Reach and Achievements
            16.2.4.4    Certifications
        16.2.5    Cadila Pharmaceuticals Ltd.
            16.2.5.1    Company Overview
            16.2.5.2    Product Portfolio
            16.2.5.3    Demographic Reach and Achievements
            16.2.5.4    Certifications
        16.2.6    Torrent Pharmaceuticals Ltd.
            16.2.6.1    Company Overview
            16.2.6.2    Product Portfolio
            16.2.6.3    Demographic Reach and Achievements
            16.2.6.4    Certifications
        16.2.7    Reliance Life Sciences Private Limited
            16.2.7.1    Company Overview
            16.2.7.2    Product Portfolio
            16.2.7.3    Demographic Reach and Achievements
            16.2.7.4    Certifications
        16.2.8    Others
17    Key Trends and Developments in the Market

 

List of Figures and Tables

1.    Global Adalimumab Biosimilar Market: Key Industry Highlights, 2018 and 2028
2.    Global Adalimumab Biosimilar Historical Market: Breakup by Product (USD Million), 2018-2022
3.    Global Adalimumab Biosimilar Market Forecast: Breakup by Product (USD Million), 2023-2028
4.    Global Adalimumab Biosimilar Historical Market: Breakup by Distribution Channel (USD Million), 2018-2022
5.    Global Adalimumab Biosimilar Market Forecast: Breakup by Distribution Channel (USD Million), 2023-2028
6.    Global Adalimumab Biosimilar Historical Market: Breakup by Region (USD Million), 2018-2022
7.    Global Adalimumab Biosimilar Market Forecast: Breakup by Region (USD Million), 2023-2028
8.    North America Adalimumab Biosimilar Historical Market: Breakup by Country (USD Million), 2018-2022
9.    North America Adalimumab Biosimilar Market Forecast: Breakup by Country (USD Million), 2023-2028
10.    Europe Adalimumab Biosimilar Historical Market: Breakup by Country (USD Million), 2018-2022
11.    Europe Adalimumab Biosimilar Market Forecast: Breakup by Country (USD Million), 2023-2028
12.    Asia Pacific Adalimumab Biosimilar Historical Market: Breakup by Country (USD Million), 2018-2022
13.    Asia Pacific Adalimumab Biosimilar Market Forecast: Breakup by Country (USD Million), 2023-2028
14.    Latin America Adalimumab Biosimilar Historical Market: Breakup by Country (USD Million), 2018-2022
15.    Latin America Adalimumab Biosimilar Market Forecast: Breakup by Country (USD Million), 2023-2028
16.    Middle East and Africa Adalimumab Biosimilar Historical Market: Breakup by Country (USD Million), 2018-2022
17.    Middle East and Africa Adalimumab Biosimilar Market Forecast: Breakup by Country (USD Million), 2023-2028
18.    Global Adalimumab Biosimilar Market Structure

Key Questions Answered in the Report

The market is projected to grow at a CAGR of 17.60% between 2023 and 2028.

The major drivers of the market include the presence of numerous large-scale testing laboratories, rising incidence of rheumatoid arthritis, growing biotechnology corporations, increasing focus to develop generic and biosimilar products, rise in approvals of the new biosimilars, and growing investments in the research and development of the new adalimumab biosimilars.

The growing geriatric population and proliferation of skin disorders are the key industry trends propelling the market's growth.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The different products are exemptia, adalirel, and cipleumab, among others.

The several distribution channels in the global adalimumab biosimilar market are hospital pharmacies and retail pharmacies, among others.

The major players in the industry are Alfred E. Tiefenbacher (GmbH & Co. KG), Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Cadila Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., and Reliance Life Sciences Private Limited, among others.

Analyst Review

The growing geriatric population drives the global adalimumab biosimilar market. Aided by the rising incidence of rheumatoid arthritis and the proliferation of skin disorders, the market is expected to grow at a CAGR of 17.60% in the forecast period of 2023-2028.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. The different products are exemptia, adalirel, and cipleumab, among others. The several distribution channels of the market are hospital pharmacies and retail pharmacies, among others. The major regional markets for the adalimumab biosimilar are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The key players in the global adalimumab biosimilar market are Alfred E. Tiefenbacher (GmbH & Co. KG), Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Cadila Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., and Reliance Life Sciences Private Limited, among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER